Recent Posts
-
Is clascoterone (Breezula) likely to avoid finasteride-style side effects? A beginner-friendly safety reality check
What “topical and local” does and does not guarantee, what regulators already warn about for clascoterone in acne, and what is still unknown for the 5% hair-loss solution after December 2025 topline results.
-
The “539%” question: how to read clascoterone (Breezula) Phase 3 topline hair-count claims without fooling yourself
What “539% relative improvement in Target-Area Hair Count” can mean, why it can be misleading without absolute numbers, and what details to wait for beyond a press release.
-
Clascoterone (Breezula) for hair loss: what it is, what the trials suggest, and what is still unknown (December 2025)
What clascoterone (Breezula) is, what December 2025 Phase 3 topline results suggest, and what remains unknown.
-
Why clascoterone (Breezula) is being called a “new mechanism” for male pattern hair loss (and why that phrase needs context)
A careful explanation of what “new mechanism” means in hair loss, how clascoterone differs from minoxidil and finasteride, and what evidence is still missing after December 2025 Phase 3 topline results.